Incyte Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Incyte kazanç ve gelirin sırasıyla yıllık 0.8% ve 2% oranında artacağı tahmin edilmektedir. EPS'nin azalması beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 19.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

0.8%

Kazanç büyüme oranı

-0.55%

EPS büyüme oranı

Biotechs kazanç büyümesi	23.7%
Gelir büyüme oranı	2.0%
Gelecekteki özkaynak getirisi	19.58%
Analist kapsamı	Good
Son güncelleme	31 Oct 2025

Gelecekteki son büyüme güncellemeleri

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 31

Recent updates

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 31

Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio

Oct 28

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Aug 14

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Aug 06

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Aug 22 Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Incyte: A Potential GARP Superstar

Feb 27

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:INCY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	5,980	1,544	1,670	2,178	19
12/31/2026	5,476	1,335	1,603	1,690	21
12/31/2025	4,967	1,218	1,376	1,298	20
9/30/2025	4,813	1,189	1,172	1,251	N/A
6/30/2025	4,585	871	946	1,003	N/A
3/31/2025	4,413	21	289	383	N/A
12/31/2024	4,241	33	235	335	N/A
9/30/2024	4,076	32	17	102	N/A
6/30/2024	3,857	97	-140	-61	N/A
3/31/2024	3,768	745	791	821	N/A
12/31/2023	3,696	598	449	496	N/A
9/30/2023	3,609	425	566	632	N/A
6/30/2023	3,513	366	698	781	N/A
3/31/2023	3,470	324	561	649	N/A
12/31/2022	3,395	341	892	970	N/A
9/30/2022	3,331	876	711	802	N/A
6/30/2022	3,320	945	665	760	N/A
3/31/2022	3,115	933	609	759	N/A
12/31/2021	2,986	949	568	749	N/A
9/30/2021	2,913	535	543	741	N/A
6/30/2021	2,721	338	450	668	N/A
3/31/2021	2,703	478	569	765	N/A
12/31/2020	2,667	-296	-312	-125	N/A
9/30/2020	2,457	-335	-266	-100	N/A
6/30/2020	2,388	-191	-108	-12	N/A
3/31/2020	2,229	-376	-227	-128	N/A
12/31/2019	2,159	447	633	711	N/A
9/30/2019	2,108	405	589	663	N/A
6/30/2019	2,006	306	N/A	592	N/A
3/31/2019	1,997	253	N/A	471	N/A
12/31/2018	1,882	109	N/A	336	N/A
9/30/2018	1,798	-109	N/A	163	N/A
6/30/2018	1,729	-102	N/A	17	N/A
3/31/2018	1,534	-167	N/A	101	N/A
12/31/2017	1,536	-313	N/A	-93	N/A
9/30/2017	1,419	-155	N/A	91	N/A
6/30/2017	1,306	-154	N/A	133	N/A
3/31/2017	1,226	-107	N/A	34	N/A
12/31/2016	1,106	104	N/A	305	N/A
9/30/2016	1,023	151	N/A	280	N/A
6/30/2016	941	74	N/A	193	N/A
3/31/2016	858	49	N/A	189	N/A
12/31/2015	754	7	N/A	89	N/A
9/30/2015	634	-86	N/A	61	N/A
6/30/2015	644	13	N/A	81	N/A
3/31/2015	581	-33	N/A	53	N/A
12/31/2014	511	-48	N/A	26	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: INCY 'nin tahmini kazanç büyümesi (yıllık 0.8% ) tasarruf oranının ( 3.1% ) altındadır.

Kazançlar ve Piyasa: INCY şirketinin kazançlarının (yıllık 0.8% ) US pazarından (yıllık 16.1% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: INCY şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: INCY şirketinin gelirinin (yıllık 2% ) US pazarından (yıllık 10.5% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: INCY şirketinin gelirinin (yıllık 2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: INCY 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 19.6 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/11/03 16:24
Gün Sonu Hisse Fiyatı	2025/10/31 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Incyte Corporation 50 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ying Huang	Barclays

Incyte Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Incyte Corporation Revises Earnings Guidance for the Fiscal Year 2025

Price target increased by 7.2% to US$80.83

Consensus EPS estimates increase by 18%

Incyte Corporation Raises Revenue Guidance for the Fiscal Year 2025

Incyte Corporation Revises Revenue Guidance for the Year 2025

Recent updates

Insufficient new directors

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Fiscal Year 2025

Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Eli Lilly and Company's Baricitinib Delivers Near- Complete Scalarched Hair Regrowth At One Year for Adoption of Baricitinib

Incyte Announces Phase 1 Results for Its Tgfbr2xpd-1 Bispecific Antibody in Advanced Colorectal Cancer and Kras G12d Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Incyte Corporation to Report Q3, 2025 Results on Oct 28, 2025

Incyte Corporation Appoints Thomas Tray as Principal Financial Officer, Effective as of September 16, 2025

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer, Effective September 22, 2025

Incyte Announces Additional FDA Approval of Opzelura®? (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte Announces Executive Changes, Effective August 25, 2025

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Actuate Therapeutics, Inc. to Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Price target increased by 7.2% to US$80.83

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Incyte Corporation Announces Departure of Christiana Stamoulis as Executive Vice President, Effective September 16, 2025

Consensus EPS estimates increase by 18%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Raises Revenue Guidance for the Fiscal Year 2025

Executive VP & Chief Medical Officer recently sold US$1.0m worth of stock

Incyte Corporation to Report Q2, 2025 Results on Jul 29, 2025

Insider recently sold US$743k worth of stock

Incyte Corporation Announces Chief Executive Officer Changes

Incyte Announces Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis

Incyte Announces FDA Approval of Monjuvi®? in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Incyte Announces Phase 3 Data for it's Retifanlimab (Zynyz®?) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Corporation Announces FDA Approval of Zynyz (Retifanlimab-Llwr) Making It the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Incyte Corporation, Annual General Meeting, Jun 10, 2025

Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Revenue Guidance for the Year 2025

Incyte Corporation to Report Q1, 2025 Results on Apr 29, 2025

Insider recently sold US$1.3m worth of stock

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Lilly's baricitinib Delivered High Rates of Hair Regrowth for Adolescents with Severe Alopecia Areata in Phase 3 BRAVE-AA-PEDS Study

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% in Patients with Prurigo Nodularis at 2025 American Academy of Dermatology Annual Meeting

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & Chief Medical Officer recently sold US$898k worth of stock

Incyte Corporation to Report Q4, 2024 Results on Feb 10, 2025

Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte Corporation Announces Retirement of Barry P. Flannelly as Executive Vice President, Effective July 31, 2025

Incyte: Multiple Drug Launches Bode Well For Future Growth

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 15%

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Consensus EPS estimates fall by 13%

Insufficient new directors

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided